GEP201606568B - Compositions for the treatment of neurologic disorders - Google Patents
Compositions for the treatment of neurologic disordersInfo
- Publication number
- GEP201606568B GEP201606568B GEAP201213272A GEAP2012013272A GEP201606568B GE P201606568 B GEP201606568 B GE P201606568B GE AP201213272 A GEAP201213272 A GE AP201213272A GE AP2012013272 A GEAP2012013272 A GE AP2012013272A GE P201606568 B GEP201606568 B GE P201606568B
- Authority
- GE
- Georgia
- Prior art keywords
- acid
- compositions
- treatment
- neurologic disorders
- gamma
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 title 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940098330 gamma linoleic acid Drugs 0.000 abstract 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 abstract 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 abstract 2
- 235000020778 linoleic acid Nutrition 0.000 abstract 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 abstract 2
- 150000004671 saturated fatty acids Chemical class 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 235000010382 gamma-tocopherol Nutrition 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
- 239000002478 γ-tocopherol Substances 0.000 abstract 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469081P | 2011-03-29 | 2011-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP201606568B true GEP201606568B (en) | 2016-11-10 |
Family
ID=46275907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201213272A GEP201606568B (en) | 2011-03-29 | 2012-03-28 | Compositions for the treatment of neurologic disorders |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120252888A1 (enExample) |
| EP (1) | EP2691086B1 (enExample) |
| JP (1) | JP6092843B2 (enExample) |
| CN (1) | CN104010634B (enExample) |
| AU (1) | AU2012235869B2 (enExample) |
| BR (1) | BR112013025088B1 (enExample) |
| CA (1) | CA2831506C (enExample) |
| CY (1) | CY1117828T1 (enExample) |
| DK (1) | DK2691086T3 (enExample) |
| EA (1) | EA025232B1 (enExample) |
| ES (1) | ES2585066T3 (enExample) |
| GE (1) | GEP201606568B (enExample) |
| HR (1) | HRP20160939T1 (enExample) |
| HU (1) | HUE028065T2 (enExample) |
| IL (1) | IL228541A (enExample) |
| MX (1) | MX2013011295A (enExample) |
| PL (1) | PL2691086T3 (enExample) |
| UA (1) | UA114706C2 (enExample) |
| WO (1) | WO2012131493A1 (enExample) |
| ZA (1) | ZA201307256B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| ITMI20130354A1 (it) | 2013-03-08 | 2014-09-09 | Again Life Italia Srl | Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie. |
| US20160279095A1 (en) * | 2013-11-12 | 2016-09-29 | Abbott Laboratories | Use of nutritional compositions including natural vitamin e, and polyunsaturated fatty acid |
| TWI725937B (zh) * | 2014-06-06 | 2021-05-01 | 美商海洋原料公司 | ω-３組成物、劑型及使用方法 |
| EP3277101A4 (en) * | 2014-11-07 | 2019-01-16 | Vadakkemuri, Mathew Jolly | OPTIMIZED NUTRITION FATTY ACID COMPOSITION |
| DE102015109352A1 (de) * | 2015-06-12 | 2016-12-15 | K. D. Pharma Bexbach Gmbh | Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n) |
| AR102008A1 (es) * | 2015-09-24 | 2017-01-25 | Brix S R L | Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas |
| WO2017213490A1 (en) | 2016-06-10 | 2017-12-14 | N.V. Nutricia | Method for controlling neuroinflammation |
| EP3534884A1 (en) | 2016-11-04 | 2019-09-11 | Immd SP. Zo.o | Intelligent delivery of ingested and absorbed molecules |
| CN109125311A (zh) * | 2018-06-26 | 2019-01-04 | 东南大学 | 预防或治疗阿尔茨海默症的药物组合物及其应用 |
| WO2022170232A1 (en) * | 2021-02-08 | 2022-08-11 | Synaptogenix, Inc. | Treatment of multiple sclerosis using pkc activators |
| WO2022170226A1 (en) * | 2021-02-08 | 2022-08-11 | Synaptogenix, Inc. | Treatment of optic nerve inflammation using pkc activators |
| WO2023018703A1 (en) * | 2021-08-09 | 2023-02-16 | Kentucky Equine Research, Inc. | Compositions and methods for modulating equine fatty acid profiles |
| WO2026041813A1 (en) * | 2024-08-23 | 2026-02-26 | University Of Alberta | A lipid emulsion for brain regeneration and optimizing brain development via parenteral or enteral administration |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601399D0 (en) * | 1986-01-21 | 1986-02-26 | Delta Iota Ltd | Information transmission/processing |
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| GB8813766D0 (en) | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| GB9001121D0 (en) * | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
| PH31403A (en) * | 1991-03-01 | 1998-10-29 | Warner Lambert Co | Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same. |
| GB9111900D0 (en) * | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| JP3283274B2 (ja) * | 1991-06-15 | 2002-05-20 | サントリー株式会社 | 新規組成物 |
| GB9506837D0 (en) * | 1995-04-03 | 1995-05-24 | Scotia Holdings Plc | Triglycerides |
| DE19757414A1 (de) * | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| US7045683B2 (en) | 2001-05-04 | 2006-05-16 | Abbott Laboratories | Δ4-desaturase genes and uses thereof |
| US20020198177A1 (en) * | 2001-05-30 | 2002-12-26 | Horrobin David Frederick | Coenzyme Q and EPA |
| DK1417211T3 (da) | 2001-07-27 | 2007-10-08 | Neptune Technologies & Bioress | Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse |
| US20030144219A1 (en) * | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US20050080109A1 (en) | 2003-10-09 | 2005-04-14 | Papas Andreas M. | Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis |
| US9265745B2 (en) * | 2005-12-21 | 2016-02-23 | Brudy Technology S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
| US20090196862A1 (en) * | 2008-01-22 | 2009-08-06 | William Davis | High dosage Vitamin D |
| JP2010155799A (ja) * | 2008-12-26 | 2010-07-15 | Fujifilm Corp | 粉末組成物及びそれを含む食品 |
| CN102438468B (zh) * | 2009-04-17 | 2014-06-04 | 纳塔克制药有限公司 | 富含低含量植烷酸的ω-3脂肪酸的组合物 |
-
2012
- 2012-03-27 US US13/431,429 patent/US20120252888A1/en not_active Abandoned
- 2012-03-28 HU HUE12727411A patent/HUE028065T2/en unknown
- 2012-03-28 CA CA2831506A patent/CA2831506C/en not_active Expired - Fee Related
- 2012-03-28 PL PL12727411.6T patent/PL2691086T3/pl unknown
- 2012-03-28 EP EP12727411.6A patent/EP2691086B1/en not_active Revoked
- 2012-03-28 DK DK12727411.6T patent/DK2691086T3/en active
- 2012-03-28 AU AU2012235869A patent/AU2012235869B2/en not_active Ceased
- 2012-03-28 CN CN201280026514.3A patent/CN104010634B/zh not_active Expired - Fee Related
- 2012-03-28 WO PCT/IB2012/000824 patent/WO2012131493A1/en not_active Ceased
- 2012-03-28 JP JP2014501739A patent/JP6092843B2/ja not_active Expired - Fee Related
- 2012-03-28 UA UAA201312638A patent/UA114706C2/uk unknown
- 2012-03-28 BR BR112013025088-7A patent/BR112013025088B1/pt not_active IP Right Cessation
- 2012-03-28 EA EA201391407A patent/EA025232B1/ru not_active IP Right Cessation
- 2012-03-28 GE GEAP201213272A patent/GEP201606568B/en unknown
- 2012-03-28 HR HRP20160939TT patent/HRP20160939T1/hr unknown
- 2012-03-28 ES ES12727411.6T patent/ES2585066T3/es active Active
- 2012-03-28 MX MX2013011295A patent/MX2013011295A/es not_active Application Discontinuation
-
2013
- 2013-09-27 ZA ZA2013/07256A patent/ZA201307256B/en unknown
- 2013-09-29 IL IL228541A patent/IL228541A/en active IP Right Grant
-
2016
- 2016-07-26 CY CY20161100730T patent/CY1117828T1/el unknown
-
2019
- 2019-05-22 US US16/419,213 patent/US20190343774A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ616554A (en) | 2015-10-30 |
| MX2013011295A (es) | 2014-11-10 |
| HK1194665A1 (zh) | 2014-10-24 |
| BR112013025088B1 (pt) | 2021-12-14 |
| DK2691086T3 (en) | 2016-08-15 |
| HUE028065T2 (en) | 2016-11-28 |
| ZA201307256B (en) | 2014-12-23 |
| CN104010634B (zh) | 2017-06-09 |
| UA114706C2 (uk) | 2017-07-25 |
| PL2691086T3 (pl) | 2016-12-30 |
| CY1117828T1 (el) | 2017-05-17 |
| BR112013025088A2 (pt) | 2017-02-14 |
| JP2014512351A (ja) | 2014-05-22 |
| CN104010634A (zh) | 2014-08-27 |
| AU2012235869A1 (en) | 2013-10-17 |
| ES2585066T3 (es) | 2016-10-03 |
| US20120252888A1 (en) | 2012-10-04 |
| WO2012131493A1 (en) | 2012-10-04 |
| US20190343774A1 (en) | 2019-11-14 |
| JP6092843B2 (ja) | 2017-03-08 |
| AU2012235869B2 (en) | 2017-04-20 |
| CA2831506C (en) | 2019-07-09 |
| EA201391407A1 (ru) | 2014-03-31 |
| EP2691086A1 (en) | 2014-02-05 |
| EP2691086B1 (en) | 2016-04-27 |
| HRP20160939T1 (hr) | 2016-10-07 |
| IL228541A0 (en) | 2013-12-31 |
| IL228541A (en) | 2017-11-30 |
| CA2831506A1 (en) | 2012-10-04 |
| EA025232B1 (ru) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500105A1 (en) | Fatty acid compositions | |
| MX2011011842A (es) | Composiciones, metodos y equipos para acidos grasos poliinsaturados a partir de microalgas. | |
| HK1206248A1 (en) | Compositions of statins and omega-3 fatty acids | |
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| PT2408426T (pt) | Composições oftálmicas baseadas em ácidos gordos poliinsaturados ómega 3 e ómega 6 | |
| MX372724B (es) | Formulaciones de acido eicosapentaenoico (epa). | |
| MX2016004487A (es) | Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados. | |
| PE20170431A1 (es) | Lipido que comprende acido docosapentaenoico | |
| WO2014074552A3 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| EA201591680A1 (ru) | Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий | |
| EA201391407A1 (ru) | Композиции для лечения нервных расстройств | |
| NZ630210A (en) | Nutritional compositions including rrr -alpha tocopherol and polyunsaturated fatty acids | |
| HK1209286A1 (en) | Removal of undesired components from oil compositions | |
| MX2015011767A (es) | Composiciones de aceite crudo de algas. | |
| MX383445B (es) | Composiciones alimenticias para mascotas. | |
| MA40417A (fr) | Mélange d'acides gras et de palmitoyl éthanolamide pour utilisation dans le traitement de pathologies inflammatoires et allergiques | |
| IN2012DN02228A (enExample) | ||
| WO2016040570A3 (en) | Dietary emulsion formulations and methods for using the same | |
| PL3784044T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| WO2014165190A3 (en) | Compositions comprising docosapentaenoic acid and methods of use | |
| PL3809858T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| EP2928314A4 (en) | OXIDIZED STABILIZED FATS CONTAINING OMEGA 3 POLYUNSATURATED FATTY ACIDS AND THEIR USES | |
| PL3809860T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| PL3560342T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| PH12017500738A1 (en) | Feeding algae to cattle at low doses to produce high omega 3 levels in beef |